Maui Derm Hawaii 2025 to feature Xstrahl’s Dual Modality Treatment Solution for Dermatologists
Radiant™ Aura is a painless, non-surgical office-based radiation therapy treatment option for patients with non-melanoma skin cancers (NMSC) and keloid scarring
Visit Xstrahl at Maui Derm Hawaii 2025 at the Grand Wailea Hotel in Maui, HI, from January 20-24, 2025
Xstrahl, a global leader in the delivery of superficial and orthovoltage radiation therapy devices and preclinical radiation research systems, will feature Radiant Aura at the Maui Derm Hawaii 2025 meeting, January 20-24, 2025. Radiant Aura is a low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Radiant Aura is the smallest, office-based radiation therapy device for dermatology practices available on the market today. It is the only system that delivers both eBt and superficial radiation therapy (SRT) to give dermatologists multiple treatment options for their NMSC patients.
“We’re pleased to feature Radiant Aura at this year’s Maui Derm Hawaii 2025 Meeting,” said Adrian Treverton, CEO of Xstrahl. “Radiant Aura is a painless non-surgical skin cancer treatment alternative available to support the delivery of office-based radiation therapy for patients with NMSC when surgery is not possible, contraindicated, or simply not preferred due to cosmetic concerns.”
Each year, Maui Derm Hawaii includes lectures, panel discussions and workshops that allow an in-depth look at advancements in dermatology. Visit Xstrahl at Maui Derm Hawaii 2025 at the Grand Wailea Hotel in Maui, HI, January 20-24, 2025.
To be placed on the VIP List for private events at the conference, please email kellywithers@xstrahl.com.
To learn more about Radiant Aura, visit radiant-therapy.com
To learn more about all Xstrahl clinical and research systems, visit www.xstrahl.com
About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.
